Arkolith/Insider Trading/VIVO/Form 4

Serafini-Lamanna Tony

Executive VP-DiagnosticsMERIDIAN BIOSCIENCE INC (VIVO) · full profile →Form 4 · filed Jan 31, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2023Grant(A)8K——43K
Jan 31, 2023Disposed to issuer(D)43K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2023Disposed to issuer(D)12K$15.12$176K0
Jan 31, 2023Disposed to issuer(D)4K$27.03$108K0
Jan 31, 2023Disposed to issuer(D)10K$19.40$194K0
Jan 31, 2023Disposed to issuer(D)12K$15.52$188K0

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001567619-23-001527) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML